Arcturus Therapeutics

Arcturus Therapeutics News & Events

Arcturus Therapeutics Expands Operations in San Diego, CA

November 3, 2014

San Diego, Calif., Nov 3, 2014 Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing orphan diseases, today announced the expansion of operations from the Johnson and Johnson Innovation Center to their new office and laboratory space at the prestigious Torrey Ridge Science Center (10628 Science Center Drive, Previously Pfizer Labs). The new headquarters includes over 10,000 square feet of office and laboratory space, sufficient to support RNA drug discovery and development.

“The Arcturus story began at the cutting edge Johnson and Johnson Innovation Center here in San Diego. Today, we are ‘graduating’ from the incubator space and moving into top-tier facilities that will enable us to execute our vision of bringing transformational life-saving RNA medicines to patients,” said Joseph E. Payne, president and CEO of Arcturus Therapeutics, Inc. “We are expanding our work force and hiring key individuals to help us develop premier RNA medicines, such as our lead rare disease drug candidate, LUNAR-101, for treatment of transthyretin-mediated amyloidosis.”

“San Diego is a city of innovation. Arcturus Therapeutics is an excellent example of the region’s entrepreneurial spirit. Outstanding high-growth biotechnology companies like Arcturus are making us a global leader in technological breakthroughs while also providing high quality jobs for San Diegans here at home,” said Kevin Faulconer, Mayor of San Diego.

About Transthyretin (TTR)-Mediated Amyloidosis
Transthyretin (TTR)-mediated amyloidosis is a genetically mediated fatal disease caused by mutations in the TTR gene. Mutated TTR, which is mainly synthesized in the liver, causes errant amyloid proteins to aggregate and deposit, destroying body organs and tissue, such as the peripheral nerves and heart. TTR-mediated cardiomyopathy (FAC) affects approximately 40,000 people with the mean survival of ~2.5 years. TTR-mediated polyneuropathy (FAP) affects at least 10,000 people. There is a substantial unmet need for effective medicines for patients suffering from TTR-mediated diseases.

About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNARTM, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics.  The company owns Unlocked Nucleic Acid (UNATM) chemistry technology and patent portfolio (34 patents, USPTO granted) enabling the targeting of any gene in the human genome. For more information, visit www.ArcturusRx.com.

#   #   #